Author

C. Holohan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

D. B. Longley· 2 shared P. D. Dunne· 2 shared A. E. Ryan· 1 shared A. Gilmore· 1 shared A. J. McIntyre· 1 shared A. Lees· 1 shared A. M. McCorry· 1 shared C. McCann· 1 shared

Activity by Year

2017-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. B. Longley

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

FLIP(L) determines p53 induced life or death

A. Lees, A. J. McIntyre, F. Falcone, N. T. Crawford, C. McCann, G. P. Quinn, J. Z. Roberts, T. Sessler, P. F. Gallagher, K. McAllister, K. McLaughlin, W. L. Allen, C. Holohan, L. J. Egan, A. E. Ryan, , S. S. McDade

This study identifies FLIP(L) as a p53 target that determines cell fate by promoting cell cycle arrest and inhibiting apoptosis.

bioRxiv · Nov 28, 2019 · PreprintCancer Biology

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer

P. D. Dunne, H. G. Coleman, P. Bankhead, M. Alderdice, R. T. Gray, S. McQuaid, V. Bingham, M. B. Loughrey, J. A. James, A. M. McCorry, A. Gilmore, C. Holohan, D. Klingbiel, S. Tejpar, P. G. Johnston, , M. Lawler

The paper identifies Bcl-xL as a prognostic biomarker and predictor of response to adjuvant chemotherapy in BRAF-mutant stage II/III colon cancer using gene expression and immunohistochemistry validation.

bioRxiv · Oct 23, 2017Cancer Biology